NCT04511026 is a Phase 2 clinical trial of Lymphoseek in Endometrial Cancer, sponsored by Stanford University.

Who is sponsoring NCT04511026?

NCT04511026 is sponsored by Stanford University.

What drugs are being tested in NCT04511026?

Interventions in NCT04511026: Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG), Neoprobe Gamma Detection System NPB11L(Model1102).

What condition does NCT04511026 study?

NCT04511026 studies Endometrial Cancer.

Is NCT04511026 still recruiting?

NCT04511026 is currently terminated. Last updated 11 October 2023.

Are results published for NCT04511026?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-10-11 · How we verify

NCT04511026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

Terminated Phase 2 Results posted Last updated 11 October 2023

What this trial tests

Phase 2 trial testing Lymphoseek in Endometrial Cancer in 6 participants. Terminated before completion.

Timeline

20 January 2021

Primary endpoint
10 June 2021

10 June 2021

Quick facts

Lead sponsor	Stanford University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	6
Start date	20 January 2021
Primary completion	10 June 2021
Estimated completion	10 June 2021
Sites	1 location across United States

Drugs / interventions tested

Lymphoseek — full drug profile →
Single Photon Emission Computed Tomography (SPECT)
Indocyanine Green (ICG) — full drug profile →
Neoprobe Gamma Detection System NPB11L(Model1102)

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Stanford University

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Bilateral SLNs Primary · during surgery, an average of 3 hours

A sentinel lymph node will be defined as being detected if it is detected on the pre-operative SPECT/CT imaging scan or intraoperatively using near-infrared imaging or the handheld gamma detection device.

Group	Value	95% CI
Lymphoseek/SPECT-CT/Indocyanine	6

Overall Detection of SLN Detection Secondary · during surgery, an average of 3 hours

For each subject, an assessment will be made of whether there was overall sentinel node detection. A sentinel lymph node will be defined as being detected if it is detected on the pre-operative SPECT/CT imaging scan or intraoperatively using near-infrared imaging or the handheld gamma detection device. If at least one SLN is detected (on any side), then this outcome will be considered a 'Yes'.

Group	Value	95% CI
Lymphoseek/SPECT-CT/Indocyanine	6

Number of SLNs Detected by Lymphoseek: Secondary · during surgery, an average of 3 hours

The number of sentinel lymph nodes detected by Lymphoseek will be assessed. A sentinel lymph node will be defined as being detected by Lymphoseek if it is detected using the pre-operative SPECT/CT imaging scan and/or intraoperatively using the gamma detection device.

Group	Value	95% CI
Lymphoseek/SPECT-CT/Indocyanine	0

Number of SLNs Detected by Indocyanine Green Secondary · during surgery, an average of 3 hours

Number of SLNs detected by Indocyanine Green: The location and number of sentinel lymph nodes detected by Indocyanine Green will be assessed. A sentinel lymph node will be defined as being detected by Indocyanine Green if it is detected intraoperatively using near-infrared imaging only and not by the gamma detection device.

Group	Value	95% CI
Lymphoseek/SPECT-CT/Indocyanine	28

Location of SLNs Detected by Indocyanine Green Secondary · during surgery, an average of 3 hours

Location of SLNs detected by Indocyanine Green: The location and number of sentinel lymph nodes detected by Indocyanine Green will be assessed. A sentinel lymph node will be defined as being detected by Indocyanine Green if it is detected intraoperatively using near-infrared imaging only and not by the gamma detection device.

Common Iliac

Group	Value	95% CI
Right-Sided SLN Locations	2
Left-Sided SLN Locations	1

External Iliac

Group	Value	95% CI
Right-Sided SLN Locations	8
Left-Sided SLN Locations	9

Hypogastric

Group	Value	95% CI
Right-Sided SLN Locations	0
Left-Sided SLN Locations	1

Obturator

Group	Value	95% CI
Right-Sided SLN Locations	1
Left-Sided SLN Locations	6

Sponsor's own description

The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.
Reddy RA, Moon AS, Chow S, Heilbroner L, et al · · 2022 · cited 3× · PMID 35958955 · DOI 10.1016/j.gore.2022.101054

Verify or expand the search:

Other trials of Lymphoseek

Trials testing the same drug.

NCT03405142 — Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph No · Phase 2 · completed
NCT02287675 — Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer · Phase 4 · completed

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04511026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04511026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing